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SUMMARY
Objective We sought to evaluate the delays, between-centre
variations in practice, and opportunity costs attributable to delays
in research governance approval of clinical trials in the United
Kingdom.
Design Retrospective survey.
Setting Research and Development (R&D) departments at
50 UK National Health Service hospital trusts governing
57 hospital sites.
Participants R&D departments participating in four
randomized multicentre clinical trials coordinated by our
Neurosciences Trials Unit.
Interventions None.
Main outcome measures Median delay between application
and research governance approval.
Results Only half of the R&D departments used the UK online
R&D form. Only a single copy of the application was required by
96% of R&D departments. The median delay between application
and research governance approval was 44 working days (inter-
quartile range 23–80). A delay of420 working days was incurred
by 43 applications (75%), of which 24 (56%) were not explicable
and 11 (20%) were attributable to local funding negotiations.
Based on the trial randomization rates at each centre, 108
patients (17% of all patients randomized) could have been
randomized during the delay, at a crude cost to funding agencies
of £53,743; if a four week delay was deemed acceptable,
75 patients (12% of all patients randomized) could have been
randomized during unacceptable delays, at a crude cost to
funding agencies of £37,700.
Conclusions The UK research governance system incurs
unacceptably long and costly delays for clinical trials. Urgent
reform is needed, including rapid design and uniform imple-
mentation of the ‘bureaucracy busting’ measures in Best
Research for Best Health.
INTRODUCTION
The future of academic medicine is under threat.1 There are
concerns that both investigator-led as well as commercial
research are relocating to parts of the world where research
appears easier to do, to the detriment of UK health, wealth
and research.2 Red tape has been one of the many recent
impediments to furthering knowledge about the causes,
prevention, and treatment of human illness in the UK.2
Slowing the conduct of clinical trials in particular runs the
risk that the identification of beneficial treatments will be
delayed, or the use of harmful treatments perpetuated.
The Department of Health has therefore promised
‘bureaucracy busting’ measures in its recent five-year vision
of a future ‘vibrant health research system’ in Best Research
for Best Health.3 A specific concern of this vision is the speed
of the process of approval of clinical trials. There are
misgivings about Best Research for Best Health because it seems
to be targeted at commercially-led trials,2,4 overall
expenditure on research promises to be lower,4 and the
document only applies to England.2 Nevertheless, its vision
of an expedited process of research governance in the UK
would benefit all clinical trials.
The process of research ethics committee approval in
the UK has improved.5 In the 1990s, UK researchers
encountered heterogeneous handling and judgement of their
proposals, but now the Central Office for Research Ethics
Committees (COREC) coordinates operational and infra-
structure arrangements, implements standards to ensure
national consistency, provides training for members of
research ethics committees and identifies computerized
solutions for procedural management.
Other impediments to clinical trials, however, are the
processes of research governance approval, management
approval and negotiation of service support costs. Without a
COREC equivalent, research governance is currently
decentralized, so accountability is unclear.6 Although many
Research and Development (R&D) departments are
operating efficiently and effectively,7 others cause unex-
plained delays which could be unethical8 or even harmful.9
Some research governance, management and funding
considerations inevitably rely on subjective judgements
which will cause variation,10 and differences in organiza-
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NHS trusts make internal authorization procedures
heterogeneous (for example, in finance and pharmacy).
But lengthy delays and poor process due to bureaucracy and
inflexibility must be avoidable.
Given these concerns about research governance, and in
view of the aspirations of Best Research for Best Health, we
sought to evaluate the delays incurred in starting clinical
trials in the era since COREC streamlined the process of
research ethics committee appraisal with a new web-based
form, in order to provide baseline data upon which the
effects of Best Research for Best Health could be judged.
METHODS
In July–August 2006, we collected data from R&D
departments in the UK by telephone, post and email
concerning their approval process for four multicentre
randomized controlled clinical trials. The four trials
coordinated by our Neurosciences Trials Unit are
comparing general anaesthetic versus local anaesthetic for
carotid surgery (GALA, www.galatrial.com); intravenous
recombinant tissue plasminogen activator versus open
control for acute ischaemic stroke (IST3, www.ist3.com);
graduated compression stockings versus routine care for the
prevention of deep vein thrombosis after stroke (CLOTS,
www.clotstrial.com); and hydrocoils versus bare platinum
coils in the endovascular treatment of intracranial
aneurysms (HELPS, http://www.helpstudy.org/). We
only collected data for UK centres that had applied for
R&D approval after the introduction of the COREC system
of ethical approval in 2000. Where exact dates were not
recorded by R&D departments (if paper and/or electronic
correspondence were unavailable to the officers at the R&D
departments at the time of this survey), mid-month dates
were ascribed (7 of 57 dates of R&D application [12%] and
3 of 57 dates of R&D approval [5%]). We collected data on
the randomization rate at each of these centres in each trial
from the time randomization began until April 2006.
RESULTS
There were 57 hospitals participating in the four trials (20
in CLOTS, 15 in IST3, 12 in GALA and 10 in HELPS),
relating to 50 individual NHS hospital trusts in England,
Wales, Scotland and Northern Ireland. Of these 57 separate
applications to R&D departments, 37 (65%) were made on
a variety of paper forms designed by each R&D department,
14 (25%) used the online R&D application form and the
remaining six (10%) had simply required all or part of the
COREC application form. Of the 18 applications made
after March 2005 (when the online R&D application form
was introduced), nine R&D departments (50%) used the
online system and the other half continued to use bespoke
paper forms. Only two R&D departments (4%) required
multiple copies of the application (five in one case and 13 in
the other).
The median delay between application and research
governance approval in all four trials was 44 working days
(inter-quartile range [IQR] 23–80) (Figure 1), and there
was a significant difference in this delay between the four
trials (Kruskal-Wallis test, chi-squared=10.4, P=0.015):
GALA 25 days (IQR 10–35), IST3 44 days (IQR 15–55),
HELPS 65 days (IQR 31–80) and CLOTS 68 days (IQR 37–
125). There was no correlation between the observed delay
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Figure 1 Number of working days taken to approve research governance applications for 57 hospitals within 50 NHS trusts
and the date of application for research governance approval
(Spearman’s rank correlation coefficient=–0.02, P=0.87).
We investigated the reasons for any delays of over four
weeks (20 working days) until approval was given, which
involved 43 R&D department applications (75%) (Figure
1). More than one reason was given for the delays incurred
at nine R&D departments. Although 24 R&D departments
(56%) could not give a reason for a delay of over four
weeks, the most common reasons cited by the others were:
local funding negotiations over support costs (20%), R&D
department staff shortages/replacements (16%), site-
specific ethical assessment of the trial was still awaited
(16%), the Principal Investigator made an error or omitted
application materials (14%), data protection checks were
required (5%), the R&D department was unclear about the
trial’s intervention (5%), and an amendment was required
(2%). Four of the five longest delays (Figure 1) involved the
CLOTS trial, and these delays were largely attributable to
negotiations over service support costs.
In April 2006, randomization into the trials had not
begun at eight centres, but at the other 49 centres the
median duration of randomization was 14.3 months (IQR
9.5–21, range 1.5–67.5). Up to this time, 620 patients had
been randomized at these centres, and the median number
of patients randomized at each centre was nine (IQR 3–17).
We multiplied the randomization rate at each individual
hospital by the delay in obtaining approval from its own
R&D department, in order to calculate the number of
patients who could have been randomized during the whole
time awaiting R&D approval. The ‘number not treated’
(NNT) during the whole time spent waiting for R&D
approval was 108 (17% [95% CI 15–21%] of all 620
patients randomized to date). If a four-week delay until
R&D approval is deemed acceptable, the NNT would have
been 75 (12% [95% CI 10–15%] of all 620 patients
randomized to date).
We calculated a crude measure of the financial cost of
these delays to funding agencies by multiplying the NNT in
each trial by the approximate per capita cost in each trial
(calculated by dividing the total funding for each trial by its
target sample size). CLOTS cost £276 per patient
(£1,378,594 / 5,000), GALA cost £286 per patient
(£1,000,000 / 3,500), HELPS cost £724 per patient
(£362,000/500) and IST3 cost £500 per patient
(£2,998,073/6,000). The cost of the patients not
randomized was £53,743 during the whole time awaiting
R&D approval, or £37,700 if a four-week delay until R&D
approval is deemed acceptable.
DISCUSSION
The processes of approval of clinical trials in the UK appear
to vary significantly between R&D departments and they
are, in general, far too slow. We found that for every eight
patients enrolled in the first few years of four clinical trials,
one further patient could have been enrolled during
unacceptable delays associated with the processes of
research governance approval, management approval and
negotiation of service support costs.
The Research Governance Framework for Health and
Social Care was introduced in England in 2001 and later
revised in 2005.11 This framework intended R&D
departments to take a ‘verifying’ role by managing and
protecting high legal, ethical and scientific standards in
research through monitoring and auditing, with each
project’s sponsor having a central role, as well as continuing
to monitor research projects’ resource use in the NHS.12
Interestingly, the R&D Forum (an independent organiza-
tion) and COREC have taken the initiative in trying to
improve the process of research governance approval.
COREC funded the creation of the online R&D application
form (https://www.rdform.org.uk/), which is populated
by data from the online COREC form and asks standard
questions about governance, management and funding at a
local study site. However, the R&D Forum does not have
authority over NHS R&D departments, so the use of the
form is not mandatory.
Only half of the R&D departments surveyed in our
study appeared to employ efficient methods such as the
online R&D application form. Variation in practice,
unnecessary delays, and under-use of information technol-
ogy are clear targets for the ‘bureaucracy busting’
developments promised by Best Research for Best Health.3
We are unaware of planned, formal evaluations of the
UK research governance system, although other researchers
have reported long delays,13–15 lost documentation,14,15
seemingly unnecessary honorary contracts and Criminal
Records Bureau checks,13,16 as well as inconsistency in
process14 because of the lack of national standards.15,16
Because UK applications for research governance
approval are always arranged by local investigators rather
than the coordinating centre, our data collection about the
process of approval was retrospective. Despite the retro-
spective design of this study, the UK centres participating in
the clinical trials were enrolled prospectively, so there were
no omissions. However, by restricting inclusion in our
survey to those trial centres where R&D approval had been
obtained, we may have underestimated the impact of
research governance by omitting lengthy delays at centres
where R&D approval had never been negotiated. Although
we had to ascribe dates for seven dates of application (12%)
and three dates of approval (5%), we thereby revealed the
lack of an electronic or paper trail at some departments.
Therefore, a prospective repetition of this study, with
independent evaluation, would be worthwhile. The
generalizability of our findings is affected by the survey 103
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being restricted to only four (albeit large) clinical trials at
only one quarter of UK R&D departments. Therefore, we
cannot accurately analyse whether there are regional
variations in the approval process. There were differences
in the delays experienced by the four clinical trials in our
study; these are likely to be due to the need for ‘service
support costs’ negotiations in one trial (CLOTS), but less so
in the others. This suggests that the UK needs a faster,
streamlined approach to assessing the financial impact of
clinical trials on Trusts. By examining the interval between
application and final approval, we did not distinguish two
important components of the R&D approval process, which
would be worthy of further scrutiny: the endorsement of
governance arrangements versus hospital management
approval.
This study has several implications for policymakers
involved with ‘busting bureaucracy’ and those governing
the research governance process. The lack of an electronic
or paper trail at a few departments clearly necessitates a
unified system—much like COREC’s—for maintaining an
audit trail. The online R&D form already presents a simple
solution, but only half of R&D departments currently use it.
For studies that have few local issues, a multicentre process
for research governance approval—again emulating
COREC—would be welcome.14 Proposed multicentre
solutions include the ‘trial passport’, already piloted in
Manchester and promoted by the R&D Forum and the UK
Clinical Research Collaboration, and Multicentre Research
and Development in Scotland. Last of all, reasonable
timescales must be imposed on R&D departments, much as
COREC imposed them on research ethics committees.
Whilst imposed timelines should be achievable within the
current R&D infrastructure, they should not unduly delay
the investigation of potentially beneficial or harmful
treatments in clinical trials; a maximum delay of four
weeks from application to approval would increase the
number of patients recruited to clinical trials in the first
couple of years by an eighth, and minimize wastage of
scarce research funds.
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